JP2014530219A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530219A5
JP2014530219A5 JP2014534512A JP2014534512A JP2014530219A5 JP 2014530219 A5 JP2014530219 A5 JP 2014530219A5 JP 2014534512 A JP2014534512 A JP 2014534512A JP 2014534512 A JP2014534512 A JP 2014534512A JP 2014530219 A5 JP2014530219 A5 JP 2014530219A5
Authority
JP
Japan
Prior art keywords
nanoparticles
nanoparticle
pharmaceutical composition
sterol
quillaja
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014534512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530219A (ja
JP6050822B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2012/051048 external-priority patent/WO2013051994A1/en
Publication of JP2014530219A publication Critical patent/JP2014530219A/ja
Publication of JP2014530219A5 publication Critical patent/JP2014530219A5/ja
Application granted granted Critical
Publication of JP6050822B2 publication Critical patent/JP6050822B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014534512A 2011-10-03 2012-10-01 ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用 Active JP6050822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542425P 2011-10-03 2011-10-03
US61/542,425 2011-10-03
PCT/SE2012/051048 WO2013051994A1 (en) 2011-10-03 2012-10-01 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds

Publications (3)

Publication Number Publication Date
JP2014530219A JP2014530219A (ja) 2014-11-17
JP2014530219A5 true JP2014530219A5 (cg-RX-API-DMAC7.html) 2015-11-19
JP6050822B2 JP6050822B2 (ja) 2016-12-21

Family

ID=47143250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534512A Active JP6050822B2 (ja) 2011-10-03 2012-10-01 ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用

Country Status (17)

Country Link
US (3) US10047116B2 (cg-RX-API-DMAC7.html)
EP (3) EP2750683B2 (cg-RX-API-DMAC7.html)
JP (1) JP6050822B2 (cg-RX-API-DMAC7.html)
KR (1) KR102090740B1 (cg-RX-API-DMAC7.html)
CN (1) CN103857403B (cg-RX-API-DMAC7.html)
AU (1) AU2012319239B2 (cg-RX-API-DMAC7.html)
CA (1) CA2850296C (cg-RX-API-DMAC7.html)
DK (2) DK3311827T3 (cg-RX-API-DMAC7.html)
ES (1) ES2673957T5 (cg-RX-API-DMAC7.html)
HR (1) HRP20180956T1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03485A (cg-RX-API-DMAC7.html)
PL (1) PL2750683T3 (cg-RX-API-DMAC7.html)
PT (1) PT2750683T (cg-RX-API-DMAC7.html)
RS (1) RS57350B1 (cg-RX-API-DMAC7.html)
TR (1) TR201808733T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013051994A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402040B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3311827T3 (da) 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
EP2777402A1 (en) 2013-03-15 2014-09-17 DSM IP Assets B.V. Solid lipid nanoparticles (I)
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
CN104382856B (zh) * 2014-12-04 2017-11-14 中国药科大学 一种去氧鬼臼毒素长循环脂质体冻干制剂
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
WO2018237109A1 (en) * 2017-06-23 2018-12-27 Yale University Nanomaterials with enhanced drug delivery efficiency
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
EP3669890A1 (en) * 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
JP7597554B2 (ja) * 2020-10-30 2024-12-10 株式会社ニップン オキシトシン受容体作動性組成物
CN116077639A (zh) * 2023-01-05 2023-05-09 国药中生生物技术研究院有限公司 雷公藤红素或其可药用衍生物在制备疫苗佐剂中的用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
GB1235022A (en) 1969-06-04 1971-06-09 Laeaeke Ag A new method for the production of cyclophosphamide
DE2124023C3 (de) 1970-05-27 1980-07-10 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
DE2845574A1 (de) 1978-10-19 1980-04-24 Deutsches Krebsforsch Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0111058B1 (en) 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DK166762B1 (da) * 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0679958B2 (ja) 1988-10-07 1994-10-12 東レ株式会社 糸条の巻取装置
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
IT1250692B (it) 1991-07-23 1995-04-21 Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9719426D0 (en) 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE59903869D1 (de) * 1998-10-14 2003-01-30 Cognis Deutschland Gmbh Verwendung von nanoskaligen sterolen und sterolestern
PL209127B1 (pl) * 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
NZ529347A (en) 2001-04-04 2008-01-31 Nordic Vaccine Technology As Use of at least one sterol capable of interacting with a nucleic acid and at least saponin to form immunostimulating complexes ( IMSCO )
BR0210994A (pt) * 2001-06-15 2004-06-08 Cornerstone Pharmaceuticals Compostos farmacêuticos e de diagnósticos contendo nanopartìculas úteis para tratamento de tecidos e células
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
JP2005514438A (ja) * 2001-12-21 2005-05-19 ソーン, デイビッド エス. 薬剤の可溶化、安定化、及び運搬のためのオリゴマー及びポリマーの使用
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
NZ539008A (en) 2002-10-02 2006-10-27 Nordic Vaccine Technology As Composition for vaccination by transdermal delivery
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050175623A1 (en) * 2004-02-10 2005-08-11 Zheng-Pin Wang Saponins as anticancer agent
EP1877067A1 (en) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
KR100641060B1 (ko) * 2005-07-22 2006-11-01 삼성전자주식회사 게이트 구조물의 제조 방법 및 이를 이용하는 반도체장치의 제조 방법
DE102006007903A1 (de) 2005-12-21 2007-07-05 VD-Werkstätten GmbH & Co KG Verfahren für die Herstellung von Möbel-Formteilen
EP1974754A4 (en) * 2006-01-18 2012-09-05 Nat Univ Corp Tokyo Med & Dent BIOMATERIAL FOR OSTEOGENESIS CONTAINING A PROMOTER OF OSTEOGENESIS AND A NANOGEL
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
WO2008080900A2 (en) * 2006-12-29 2008-07-10 Evonik Degussa Gmbh Methionine synthases with reduced product inhibition
US20080312581A1 (en) * 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Peptosomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
KR20100082825A (ko) * 2007-10-12 2010-07-20 씨에스엘 리미티드 유행성 인플루엔자 바이러스에 대항하여 면역 반응을 유발하는 방법
CA2917512C (en) * 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
CN102202689A (zh) * 2008-08-28 2011-09-28 葛兰素史密丝克莱恩生物有限公司 疫苗
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
AU2010264686A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
HRP20160798T1 (hr) * 2009-06-24 2016-08-12 Glaxosmithkline Biologicals S.A. Rekombinantni antigeni iz rsv
AU2010269148A1 (en) 2009-07-10 2012-01-19 Isconova Ab New composition
CA2826060C (en) * 2011-02-04 2019-06-18 Zoetis Llc Immunogenic bordetella bronchiseptica compositions
US20140199233A1 (en) * 2011-05-11 2014-07-17 The Regents Of The University Of California Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
DK3311827T3 (da) * 2011-10-03 2023-04-03 Canqura Oncology Ab Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser
GB201119999D0 (en) * 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
EP3632279B1 (en) 2017-10-20 2024-05-29 Corelex Shin-Ei Co., Ltd. Log roll production device

Similar Documents

Publication Publication Date Title
JP2014530219A5 (cg-RX-API-DMAC7.html)
Bezbaruah et al. Nanoparticle-based delivery systems for vaccines
Witika et al. Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications
Kyriakides et al. Biocompatibility of nanomaterials and their immunological properties
Yuan et al. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles
HRP20180956T1 (hr) Nanočestice, postupak dobivanja i njihova primjena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju karcinoma, kao i prehrambenih spojeva
Chountoulesi et al. Lyotropic liquid crystalline nanostructures as drug delivery systems and vaccine platforms
Abbaraju et al. Asymmetric silica nanoparticles with tunable head–tail structures enhance hemocompatibility and maturation of immune cells
Juere et al. In vitro dissolution, cellular membrane permeability, and anti-inflammatory response of resveratrol-encapsulated mesoporous silica nanoparticles
Zhao et al. Functionalized graphene oxide nanoparticles for cancer cell-specific delivery of antitumor drug
Colley et al. Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation
Bi et al. Layered double hydroxide-based nanocarriers for drug delivery
Ding et al. Theoretical and computational investigations of nanoparticle–biomembrane interactions in cellular delivery
Kamboj et al. Vesicular drug delivery systems: a novel approach for drug targeting
Praphakar et al. Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly (ester amide) s nanocarriers
Kumar et al. Nanomedicine in drug delivery
Yan et al. A novel type of aqueous dispersible ultrathin-layered double hydroxide nanosheets for in vivo bioimaging and drug delivery
Ali et al. Enhancing the solubility and oral bioavailability of poorly water-soluble drugs using monoolein cubosomes
Binaymotlagh et al. Liposome–hydrogel composites for controlled drug delivery applications
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
Shi et al. Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model
JP2015515992A (ja) 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
Barros et al. A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules
CN112074298B (zh) Langerin+细胞靶向
Zhao et al. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review